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Abstract
Objectives: Skin fibrosis is a main hallmark of systemic sclerosis (SSc). Clinical assessment is done semi-quantitatively using
the modified Rodnan skin score (mRSS). Objective measurements for quantifying skin fibrosis could complement the mRSS
to achieve higher reproducibility. The aim of this study was to explore the potential of suction measurements to detect
structural changes in the skin that are associated with skin fibrosis.
Methods: This clinical trial included 30 SSc patients and 30 healthy volunteers (HC). We validated a novel suction device—
the Nimble—to quantify skin stiffness in comparison to the Cutometer using the OMERACT filter.
Results: A significant difference (p< 0.05) between the skin stiffness of HC and SSc patient groups was found for each
location measured. The correlation between the measurements of forearm skin stiffness and the mRSS values was high for
the Nimble (r= 0.82) and moderate for the Cutometer (r= 0.58). A ROC analysis showed good ability for the Nimble to
distinguish between SSc patients with and without skin involvement (AUC= 0.82). Both suction devices provided excellent
reliability in all measurements on HC and SSc patients and proved face validity and feasibility.
Conclusion: Suction devices assessing skin stiffness, such as the Nimble, show clear potential to objectively quantify skin
fibrosis in SSc patients and might be promising outcome measures complementing established methods such as the mRSS.
Trial registration: Clinicaltrials.gov, NCT03644225, Registered 23 August 2018—Retrospectively registered, http://www.
clinicaltrials.gov
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Introduction
Systemic sclerosis (SSc) is a heterogenic, autoimmune, con-
nective tissue disease, characterized by vasculopathy and in-
flammation in the remodeling of tissue architecture [1].
Skin fibrosis is one main hallmark of SSc and common in
many patients with the disease [2]. It has been shown that
the severity of skin fibrosis [3, 4] and its rate of progression
[5, 6] reflect the prevalence of internal organ involvement.
According to ACR/EULAR 2013 criteria [7], skin thickening
on the fingers that extends proximal to the metacarpopha-
langeal joints is sufficient for the classification of SSc. Unfor-
tunately, diagnosing and evaluating the extent and activity
of skin involvement is sometimes difficult for clinicians, due
to the rarity of the disease and their limited experience with
its symptoms [8]. Furthermore, assessment of skin fibrosis
in SSc patients is affected by the low sensitivity and specifi-
city of outcome measures. As a consequence, therapies for
skin fibrosis could not be shown to be effective using com-
mon non-invasive quantification methods [1].
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The modified Rodnan skin score (mRSS) is the gold
standard for the clinical assessment of skin fibrosis in
SSc patients. It is based on a palpation method that as-
sesses skin thickness in combination with skin tethering
at 17 sites on the body, with scores of 0 (normal) to 3
(severe) [9]. The mRSS is the most widely used measure
for evaluating drug efficacy on skin fibrosis. Its applic-
ability, however, has only been validated for the early
disease stages of diffuse cutaneous SSc [10], and the
drawback of this method is the high inter-observer vari-
ability of about 25% [11]. Nevertheless, the mRSS-based
quantification method is the most common primary out-
come measure used in clinical trials [12, 13]. It is also a
major component of the composite outcome measure
CRISS, which has been used in recent clinical trials [14].
Furthermore, the mRSS at baseline has been shown to
predict worsening [15] or improvement [16] of skin fi-
brosis, thereby improving the definition of inclusion cri-
teria for clinical trials. Taken together, the literature
shows the utility of skin involvement measures for classi-
fying and treating SSc. However, there is an urgent need
for objective measures of skin fibrosis in order to im-
prove the design and reliability of clinical trials.
An alternative approach for quantifying skin fibrosis is
measuring the biomechanical properties of the tissue
with the suction principle [17]. Characterization of skin
mechanical properties based on the suction method has
been shown to detect relevant differences in SSc patients
[17, 18]. The most widely used suction device is the Cut-
ometer, which has demonstrated valuable applicability
for the quantification of skin involvement in SSc patients
[19]. However, the measurement is prone to errors due
to inter- and intra-observer variability [20] arising from
observer and patient movements influencing the contact
force [21–23]. These problems are associated with the
large weight and size of the Cutometer probe. With this
in mind, we developed a novel suction device with
strongly reduced probe dimensions and weight [20]. We
propose that this novel device is more effective in distin-
guishing fibrotic skin from healthy skin and therefore
could be useful for assessing skin fibrosis in SSc patients.
In the present study, we aim to validate skin suction
for use with SSc patients in accordance with the Out-
come Measures in Rheumatology (OMERACT) filter.
More specifically, the objective of this study is to assess
the capabilities of two suction devices, the Nimble and
the Cutometer, to quantify skin involvement in SSc pa-
tients in comparison with the mRSS, the current clinical
gold standard.
Materials and methods
Patients and healthy controls
Patients scheduled for a yearly routine assessment at the
University Hospital Zurich’s Department of Rheumatology
were enrolled in this study. Inclusion criteria were fulfill-
ment of ACR/EULAR 2013 criteria for the classification of
SSc and the presence of skin fibrosis as assessed by the
mRSS. Thirty age- and sex-matched healthy volunteers
(HC) were enrolled as a control group.
An interventional medical device study (registered at
www.clinicaltrials.gov: NCT03644225) was performed at
the University Hospital Zurich in accordance with the
approval obtained from the local ethics committee (Can-
tonal Ethics Committee Zurich, KEK-ZH-Nr. 2017-
01154) and from the Swiss National Agency for Thera-
peutic Products (Swissmedic, 2017-MD-0045). Each pa-
tient and control signed a written informed consent
form. The study was performed according to good clin-
ical practice (GCP) guidelines, including external moni-
toring and compliance with the Declaration of Helsinki.
Modified Rodnan skin score (mRSS)
Our study clinically assessed skin fibrosis with the mRSS
by palpation according to the standardized method [12].
All 17 body sites selected for measurement were evalu-
ated by trained clinicians. Suction measurements were
performed at four specific body sites: the left and right
dorsal forearms and the back of the left and right hands.
This is why we define mRSS4total as the sum of the mRSS
values of these four locations:
mRSS4total ¼ mRSSback of left hand
þmRSSback of right handþ
þmRSSleft dorsal forearm þmRSSright dorsal forearm
The total mRSS describing the sum of the scores of all
17 body sites will be referred to as mRSS17total.
OMERACT filter
Data analysis was based on the OMERACT filter [24]
and interpreted as follows: the face validity of the meas-
urement methods was evaluated and explained using
measurements on a controlled system (synthetic mater-
ial) that mimicked skin fibrosis (stiffer material behav-
ior). Feasibility was judged due to the duration of the
measurement and patients’ tolerance for it. Content val-
idity was interpreted as the ability of the outcome mea-
sures to distinguish between HC and SSc patients, and
the ability to differentiate between severity grades of skin
fibrosis. The correlation of the study outcome measure
with the mRSS, the clinical gold standard for quantifying
skin involvement in SSc patients, and the convergent
validity based on the correlation of the stiffness measure
of the Nimble (the novel device) with the stiffness meas-
ure of the Cutometer (the validated commercial device)
was used to analyze criterion validity. Specificity and
sensitivity of the new diagnostic method additionally
proved criterion validity. Construct validity was assessed
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through comparison of the diagnostic measure with
other related outcome measures like the mRSS17total and
lung fibrosis (high-resolution computed tomography,
HRCT). The evaluation of intraclass correlations (reli-
ability) was based on analysis of the intraclass correl-
ation coefficient (ICC).
Suction devices
We first determined the mechanical parameters with
two different devices (Fig. 1). The Cutometer MPA 580
(Courage & Khazaka electronic, Cologne, Germany) ap-
plies a defined negative pressure on the surface of the
skin, drawing it into a circular opening measuring 6 mm
in diameter. The elevation of the tissue is measured with
an optical measurement system. Our suction tests ap-
plied what is called the Mode 2 protocol, using pmax =
250mbar and a pressure ramp of 15 mbar/s. Import-
antly, based on Mueller et al. [20], we applied a correc-
tion scheme for each measurement with the Cutometer
in order to minimize the influence of the initial contact
force. The maximum tissue elevation is the outcome of
the measurement (parameter R0corr in mm).
The Nimble is a novel lightweight suction device that
minimizes operator influence on the measurement out-
come [20]. Negative pressure draws the skin into the 6-
mm probe opening until it reaches a defined height (h =
0.5 mm). The pressure (pcl) needed for this specific ele-
vation is determined in each test.
The stiffness parameters kNimble (Nimble) and kR0














In order to enable comparability with the mRSS, we
express the suction results as the skin stiffness score







kSStotal ¼ kSSback of left hand þ kSSback of right handþ
þkSSleft dorsal forearm þ kSSright dorsal forearm
kSS is the stiffness measured at a specific location
(kloc) of an SSc patient and normalized with the average
stiffness at the same location measured on the healthy
controls (k
HC
loc Þ. The kSStotal is the summation of the kSS
over the four measured locations.
Measurement procedure
One observer measured skin stiffness at four body sites,
the left and right dorsal forearms and the back of the left
and right hands, on a total of 30 SSc patients and 30
healthy controls. The observer began the measurement
procedure with the Nimble device and measured each
location four times in a row. The observer waited at least
35 s between repeated measurements at the same loca-
tion. The total measurement duration for each location
was approximately 5 min. Afterwards, the same proced-
ure was repeated with the Cutometer device. We gener-
ated an outcome parameter—tissue stiffness—for each
Fig. 1 Schemes of the working principles of the Nimble (a) and Cutometer (b) suction devices. The Nimble operates in a displacement-controlled
fashion, with negative pressure drawing the skin into the probe opening until it reaches a defined height (h). The outcome measure is the
pressure (pcl) needed for the specific tissue elevation. The Cutometer operates in a load-controlled fashion, with negative pressure drawing the
skin into the probe opening until a maximum pressure is reached. The outcome measure is the elevation corresponding to a specific suction
load. We extracted the maximum elevation (R0 in mm) for our study
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measurement. In order to apply the correction scheme
on Cutometer outcomes, the pre-deformation of the ini-
tial contact force was recorded in each measurement.
The location-specific stiffness kloc was determined as the
average of the four measurements.
Statistical analysis
Statistical analysis was performed using the Python li-
brary scipy.stats (Python Software Foundation, Delaware,
USA). The analysis included descriptive statistics, means,
standard deviation (SD), and standard error of the mean
(SEM). The ability of the devices to distinguish between
HC and SSc patients was determined using a two-sided
t-test (stats.ttest_ind) with a level of significance p < 0.05.
The reliability of the devices in distinguishing between
individual patients and healthy volunteers was calculated
using the intraclass correlation coefficient ICC [1, 2],
which is based on a random single measurement. We
used the ICC categorization of Cicchetti [25], where
ICC = 0.4 shows poor reliability of the outcome measure,
0.4 < ICC < 0.59 is fair, 0.6 < ICC < 0.74 is good, and
0.75 < ICC < 1.0 is excellent. Concurrent validity was
assessed between the stiffness measures kNimble and kR0
from the suction experiments, as well as between the
stiffness measures and the mRSS of the clinical assess-
ment. To this end, Pearson’s correlation (stats.pearsonr)
was used with the following interpretation [26]: 0.00 <
r < 0.35 indicates weak correlation, 0.36 < r < 0.67 moder-
ate correlation, and 0.68 < r < 1.0 high correlation be-
tween the outcome measures. An area under curve
(AUC) of receiver operating characteristic (ROC) ana-
lysis was performed to evaluate the discrimination be-
tween SSc with mRSS4total = 0 and mRSS
4
total > 0 of the
stiffness parameters kNimble and kR0. Youden’s index [27]
was used to evaluate the most suitable cut-off value.
Results
Demographics of SSc patients and HCs
The characteristics and demographics of the 30 SSc pa-
tients included in the trial are summarized in Table 1.
The 30 HCs were 55 ± 10.4 years old, and 23 out of 30
were female (76.7%).
We evaluated the mean and SEM of the mRSS quanti-
fication from the clinical assessment for SSc patients for
the four different body sites that were evaluated in this
study (Supplementary Fig. 1). The values for the back of
the right hand were mRSSBHR ¼ 0:73 0:17, for the left
mRSSBHL ¼ 0:67 0:16 , and for the dorsal forearms
mRSSDVR ¼ 0:43 0:14 and mRSSDVL ¼ 0:33 0:12.
Face validity and feasibility
We tested the face validity of the suction procedure on a
synthetic material. The advantage of using a synthetic
material is the control one has over mechanical proper-
ties such as Young’s modulus (E), which describes the
stiffness of a material, i.e., the relationship between the
applied force and the deformation it generates. We man-
ufactured two compliant elastomers characterized by a
stiffness corresponding to soft skin (EM1 = 74 kPa) and
stiff skin (EM2 = 110 kPa). We then measured k
Nimble and
kR0 (Fig. 2b) and performed corresponding numerical
simulations of suction, i.e., finite element (FE) analyses
using a specific constitutive model (neo-Hookean) with
corresponding material parameters (Fig. 2a). As shown
in Fig. 2b, the stiffness of Material 1 (M1) was kNim-
ble
M1 = 246.52 ± 1.69 mbar/mm and k
R0
M1 = 255.46 ±
12.3 mbar/mm (mean and SD), and for Material 2 (M2),
the stiffness was kNimbleM2 = 404.99 ± 1.33 mbar/mm and
kR0M2 = 394.77 ± 13.32 mbar/mm. These suction mea-
surements were very much in line with the computa-
tional predictions of the FE analysis (kFE-NimbleM1 =
274.10 mbar/mm, kFE-NimbleM2 = 424.10 mbar/mm, and
kFE-R0M1 = 297.62 mbar/mm, k
FE-R0
M2 = 430.29 mbar/
mm). The dashed lines indicate the relationship between
the actual stiffness of the material (Young’s modulus)
and the measured stiffness (kNimble and kR0), which
followed a linear proportionality. Thus, suction devices
can differentiate between the stiffness of materials and
have face validity to assess tissue stiffness in skin
fibrosis.
Feasibility was given, as the procedure itself took less
than 5 min per body site and the measurements were
very well tolerated by the patients without any reported
adverse event.
Content validity (comprehensiveness) of stiffness
measures
Content validity was assessed by investigating the ability
of the suction method to distinguish between HC and
SSc patients. Figure 3 depicts the mean and SEM of the
stiffness measure for each location of HC (white) and
SSc patients (gray) measured with the Nimble (Fig. 3a)
and the Cutometer (Fig. 3b). The average coefficient of
variation was larger for the Nimble (19.7%) compared to
the Cutometer (6.8%). Significant differences (p < 0.05)
between HC and SSc patients were found for each loca-
tion and for both devices.
Content validity was further assessed by examining
whether the suction devices can differentiate between se-
verity grades of skin fibrosis. Figure 4 shows the skin
stiffness scores kSSNimble (Fig. 4a) and kSSR0 (Fig. 4c)
with grouped mRSS4total values of the four measured lo-
cations. The stiffness score increased with higher
mRSS4total values suggesting good content validity. We
found significant differences between the kSSNimble and
kSSR0 of the HC group and SSc patients with mRSS4to-
tal = 0, mRSS
4
total between 1 and 3, 4 and 6, and 7 and 9.
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Criterion validity
Criterion validity can be assessed by comparing the per-
formance with the gold standard, e.g., the mRSS. We an-
alyzed Pearson’s correlation coefficient r between mRSS
and kNimble or kR0, respectively, as well as r between the
stiffness measures kR0 and kNimble (Supplementary
Table 1). Correlations between mRSS and kNimble were
found to be moderate (r = 0.47 and r = 0.57) for mea-
surements on the back of the hand and high (r = 0.82
and r = 0.74) for measurements on the dorsal forearms,
respectively. Correlations with kR0 were moderate for all
locations (r = 0.62, r = 0.56 on the back of the hands, and
r = 0.58 on the dorsal forearms). When comparing the
stiffness measures kNimble and kR0, we observed high cor-
relations for the back of the left and right hands as well
Table 1 Demographics and clinical characteristics of SSc
patients (n = 30) at baseline. Definitions of items and organ
manifestation are according to EUSTAR [28]. Data is presented
as number (n)/total valid cases (N) (%). Disease duration was
calculated as the difference between the date of the baseline
visit and the date of the first non-Raynaud’s symptom of the
disease as reported by the patient. Pulmonary hypertension was
judged on RHC after application of the DETECT score. Active
disease was defined as a score > 3 by calculating European
Scleroderma Study Group disease activity indices for systemic
sclerosis as proposed by Valentini [29]. Immunosuppressive
therapy was defined as treatment with corticosteroids
(prednisone dose ≥ 10 mg/day or other dosage forms in equal
dose) or any immunosuppressant. ACA anti-centromere
antibody, ANA antinuclear antibody, Anti-Scl-70 anti-
topoisomerase antibody, CRP C-reactive protein, HRCT high-
resolution computed tomography, FVC forced vital capacity,
mRSS modified Rodnan skin score, NYHA New York Heart
Association, VAI Valentini Activity Index
Characteristics SSc patients
Demographics
Age (mean ± SD) 58.3 ± 11.1
Sex: female 21/30 (70%)
Disease duration (mean ± SD, in years) 11.1 ± 7.9
ACR/EULAR criteria fulfilled 30/30 (100%)
Subtype
Diffuse SSc 8/30 (26.7%)
Skin/vascular
Raynaud’s phenomenon 29/30 (96.7%)
Digital ulcers (past and present) 19/30 (63.3%)
Current digital ulcers 7/28 (25%)
Pitting scars 19/29 (65.5%)
Scleredema 24/28 (85.7%)
Telangiectasia 18/30 (60%)
mRSS (mean ± SD) 7.2 ± 7.1
Abnormal nailfold capillaroscopy 26/26 (100%)
Musculoskeletal
Tendon friction rubs 0
Joint synovitis 3/28 (10.7%)
Joint contractures 11/27 (40.7%)
Muscle weakness 3/28 (10.7%)
Gastrointestinal
Esophageal symptoms 17/30 (56.6%)
Stomach symptoms 13/30 (43.3%)
Intestinal symptoms 16/30 (53.3%)
Cardiopulmonary
Dyspnea
NYHA Stage 1 11/29 (37.9%)
NYHA Stage 2 14/29 (48.3%)
NYHA Stage 3/4 4/29 (13.8%)
Table 1 Demographics and clinical characteristics of SSc
patients (n = 30) at baseline. Definitions of items and organ
manifestation are according to EUSTAR [28]. Data is presented
as number (n)/total valid cases (N) (%). Disease duration was
calculated as the difference between the date of the baseline
visit and the date of the first non-Raynaud’s symptom of the
disease as reported by the patient. Pulmonary hypertension was
judged on RHC after application of the DETECT score. Active
disease was defined as a score > 3 by calculating European
Scleroderma Study Group disease activity indices for systemic
sclerosis as proposed by Valentini [29]. Immunosuppressive
therapy was defined as treatment with corticosteroids
(prednisone dose ≥ 10 mg/day or other dosage forms in equal
dose) or any immunosuppressant. ACA anti-centromere
antibody, ANA antinuclear antibody, Anti-Scl-70 anti-
topoisomerase antibody, CRP C-reactive protein, HRCT high-
resolution computed tomography, FVC forced vital capacity,
mRSS modified Rodnan skin score, NYHA New York Heart
Association, VAI Valentini Activity Index (Continued)
Characteristics SSc patients
Diastolic dysfunction 7/28 (25%)
Conduction blocks 2/28 (7.1%)
PAH by RHC 2/28 (7.1%)
Lung fibrosis on HRCT 15/29 (51.7%)
FVC, % predicted (mean ± SD) 92.1 ± 17.5




ANA positive 30/30 (100%)
ACA positive 12/28 (42.8%)
Anti-Scl-70 positive 9/30 (30%)
Anti-RNA-polymerase III positive 8/28 (28.6%)
CRP elevation 5/27 (18.5%)
Active disease (VAI > 3) 5/26 (19.2%)
Immunosuppressive therapy 7/30 (23.3%)
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as for the right dorsal forearm (r = 0.82, r = 0.81 and r =
0.71) and a moderate correlation for measurements of
the left dorsal forearm (r = 0.64), respectively. These data
indicate a location-dependent moderate to good criter-
ion validity of the suction devices.
Another aspect of criterion validity is the specificity and
sensitivity of the new diagnostic method. To address this
point, we grouped the SSc patients into two groups: the first
group with a total mRSS4total= 0 and the second with
mRSS4total > 0. Figure 5 a and b show kSS
Nimble and kSSR0 for
the two groups. Based on this data, we performed an ROC
analysis and evaluated the most suitable cut-off value to dif-
ferentiate between normal and fibrotic skin using a calcula-
tion of the Youden’s index J. For the outcome measure of
the Nimble, we found a higher JNimble= 0.53 compared to
JR0= 0.40 and cut-off values at kSSNimble= 8 and kSSCut-
ometer= 5, respectively. ROC analysis of the accuracy of the
stiffness measure (Fig. 5c) revealed that discrimination be-
tween SSc patients with an mRSS4total= 0 and mRSS
4
total > 0
was better for the Nimble (AUC= 0.82) than for the Cut-
ometer (AUC= 0.70).
Construct validity
Construct validity can be assessed by comparing the
diagnostic measure of interest with other related out-
come measures. We analyzed the correlation of suction
measurements with other fibrotic disease measures such
as lung fibrosis measured by high-resolution computed
tomography (HRCT) (Supplementary Fig. 2) and the
total mRSS17total of the 17 locations (Supplementary
Fig. 2 a Finite element (FE) simulation of suction experiment using a neo-Hookean material model with Young’s modulus E. The 2D cross-
sectional geometry is depicted. b Estimated kNimble and kR0 for two materials, M1 and M2, with FE analysis (FE stiffness) and mean (n = 3) of
kNimble and kR0 (experimental stiffness). The dotted line indicates the linear relationship between kNimble or kR0 and the Young’s modulus of
the material
Fig. 3 Mean and SEM for HC (white) and SSc (gray) measured with the Nimble (a) and the Cutometer (b) for the four body locations, n = 30 for
each group. For all locations and both devices, significant differences were found with a paired t-test (p < 0.0)
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Fig. 3). kSSNimble measures were grouped into SSc pa-
tients with and without lung fibrosis, and the mean value
was kSSNimble = 11.54 mbar/mm for patients with lung fi-
brosis and kSSNimble = 6.32 mbar/mm for those without
(p = 0.063). The same analysis was performed for Cut-
ometer stiffness outcomes and mRSS17total. The follow-
ing mean values were observed: kSSR0 = 5.57 mbar/mm
with lung fibrosis and kSSR0 = 4.61 mbar/mm without
(p < 0.05), and mRSS17total = 8.87 for patients with lung
fibrosis detected by HRCT and mRSS17total = 5.57 for
those without (p = 0.22). For the total mRSS17total of all
17 body locations, we found high Pearson’s correlations
with the skin stiffness score kSSNimble (r = 0.73) and
kSSR0 (r = 0.66), shown in Supplementary Table 1. Add-
itionally, linear regression analysis showed increasing
skin stiffness with increasing mRSS17total (Supplementary
Fig. 3). The obtained regression values were as follows:
R2(kSSNimble) = 0.547 and R2(kSSR0) = 0.268.
Reliability
The reproducibility of the suction devices was tested by
measuring the intraclass correlation coefficient (ICC).
The ICC estimates the ability of the outcome measure to
distinguish between patients and healthy controls for
four repeated measurements at each location. We found
excellent ICC values (ICCNimble = 0.76 and ICCR0 = 0.81)
for the HC group and even higher ICC values (ICCNim-
ble = 0.91 and ICCR0 = 0.85) for SSc patients. Note that
very high ICC values were obtained with Nimble despite
its larger coefficient of variation.
Discussion
One of the main characteristics of SSc is skin fibrosis, a
condition which is marked by the massive deposition of
collagen fibers in the extracellular matrix. As a
consequence, the skin tissue becomes stiffer and thicker
and experiences tethering to the underlying tissue. With
this study, we aimed to evaluate two suction devices, the
Nimble and the Cutometer, with regard to their diagnos-
tic potential for skin fibrosis in SSc patients. Our results
confirm (Fig. 3) the ability of both suction devices to dis-
tinguish between tissue stiffness in HC and in SSc pa-
tients for all sites on the body that were measured.
The suction method provides an objective alternative to
the mRSS [17], as it induces a deformation similar to lifting
the skin between the fingers [19]. Our measurements
showed a high correlation between kNimble and mRSS for
measurements on the dorsal forearm (Supplementary
Table 1). The moderate correlation between suction out-
comes and mRSS for measurements on the back of the hand
might be associated with the influence of the anatomical fea-
tures under the skin. The presence of bones, tendons, and
vessels leads to large variability between adjacent locations
on the back of each patient’s hand. Additionally, slight tilting
of fingers or the hand can form wrinkles, which interfere
with suction measurements, leading to potential misin-
terpretation of the actual skin stiffness. As there are
several studies (e.g., [17, 30]) proving the validity of the
Cutometer, we interpret the strong correlation between
the two suction devices as an additional confirmation
of criterion validity for the Nimble. The present study
applies a correction scheme previously developed for
the Cutometer in order to minimize the influence of
the variable contact force exerted during the measure-
ments [20]. It is important to note that data analysis
without this correction leads to much worse perform-
ance and higher variability of Cutometer measure-
ments: the ICC values of kR0 fall to ICCR0 = 0.69 for HC
and ICCR0 = 0.75 for SSc patients, and the area under
the curve in ROC analysis drops to AUC = 0.66.
Fig. 4 Skin stiffness score of suction measurements correlated with mRSS values of SSc patients. a Correlation of kSSNimble with mRSS4total of the
four measured locations. The first group includes the kSSNimble for the HC group, the second the kSSNimble for the SSc patients with total mRSS4total = 0
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The value of the newly designed Nimble device in
detecting fibrotic skin was shown to be superior to
that of the Cutometer. The results in Fig. 5 could be
considered confirmation of the ability of the Nimble
to predict whether the patient’s skin is clinically in-
volved. Additionally, suction outcomes were found to
correlate with the total mRSS17total of all 17 body lo-
cations and even showed associations with other fi-
brotic disease measures (Supplementary Fig. 2). Even
though we only compared the kSS values of four body
sites with the overall disease measures of SSc, con-
formity could be observed. Intraclass correlation coef-
ficients indicated excellent reliability for the suction
method for both HC and SSc patients.
In skin fibrosis, healthy extracellular matrix is replaced
with collagen-rich connective tissue [31]. This profuse
collagen deposition results in stiffer tissue behavior [1].
This condition is currently indirectly quantified by the
mRSS method, which mainly reflects the perceived skin
thickness. However, tissue stiffness is predominantly de-
termined by the density and condition of collagen fibers,
and this does not necessarily correlate with tissue thick-
ness. Based on the present results, we propose that
measuring tissue stiffness with the suction approach is a
more appropriate way of quantifying skin fibrosis than
relying on the mRSS alone. In Fig. 2, we showed the
ability of suction measurements to accurately quantify
the stiffness of synthetic materials with different stiffness
Fig. 5 a Skin stiffness score (kSS) of Nimble measurements grouped into SSc patients with mRSS4total = 0 and mRSS
4
total > 0. b Skin stiffness score
(kSS) of Cutometer measurements grouped into SSc patients with mRSS4total = 0 and mRSS
4
total > 0. c Receiver operating characteristic (ROC)
curve tests for sensitivity and specificity of suction measures. Nimble measurements showed a larger area under the ROC curve (AUC) compared
to Cutometer measurements, indicating a better ability to distinguish between SSc patients with a total mRSS4total = 0 and SSc patients with a
total mRSS4total > 0. Cut-off values were evaluated by the Youden’s index, indicated in red
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properties. We expect a suitable suction procedure to be
able to quantify tissue stiffness due to higher collagen
deposition. Such a method, however, would not be able
to distinguish between stiffness resulting from higher
collagen density and stiffness resulting from stretched
collagen fibers due to edema.
The novel device (Nimble) was shown to provide a
promising alternative to the existing suction device (Cut-
ometer). It is easy to use and inherently safe, and the
low costs of the Nimble probe allow it to be used as a
disposable device adding to its feasibility. The Nimble’s
measurement duration was the same as for the Cut-
ometer: for four repeated measurements, it amounted to
5 min per measured location.
The main limitation of this study is the rather small
sample size when considering the heterogeneous clinical
presentation of SSc. The objective was to analyze the val-
idity of suction measurements for detecting structural skin
changes in SSc patients. While this was confirmed over
the wide range of the present patient cohort, the number
of patients with high mRSS values was rather low. The
present study also did not address sensitivity to change
over time: no longitudinal measurements were performed,
and the discrimination capacity over the course of treat-
ment was not evaluated. Similarly, due to the small sample
size, it was not possible to evaluate the influence of disease
duration on biomechanical parameters.
Conclusion
The diagnostic relevance of biomechanical measure-
ments was analyzed in a clinical trial involving 30 SSc
patients. The results of the present study fulfill the
OMERACT filter [32], including face validity, content
validity, criterion validity, construct validity, reliability,
and feasibility of suction as an objective measurement
procedure for skin involvement in SSc patients. Our re-
sults are in line with biomechanical measurements for
other fibrotic diseases [33–35]. The reliability and feasi-
bility of suction measurements suggest that this method
could be a promising complement for clinical assess-
ment of skin fibrosis in patients with SSc.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02214-y.
Additional file 1. Mean and SEM of mRSS quantification from clinical
assessment of SSc patients for the four measured locations, n = 30.
Additional file 2. Pearson’s correlation coefficient r for evaluation of
criterion and construct validity for both suction devices. Pearson’s
correlation between stiffness measures kNimble and kR0 with mRSS
(moderate to high) indicates criterion validity. Construct validity is
assessed by Pearson’s correlation between kNimble and kR0.
Additional file 3. (A) Skin stiffness score (kSS) of Nimble measurements
grouped into SSc patients with no lung fibrosis on HRCT and presence of
lung fibrosis on HRCT. The horizontal line indicates the mean of kSSNimble.
(B) Skin stiffness score (kSS) of Cutometer measurements grouped into
SSc patients with no lung fibrosis on HRCT and presence of lung fibrosis
on HRCT. The horizontal line indicates the mean of kSSR0. (C) Total
mRSS17total of 17 locations grouped into SSc patients with no lung
fibrosis on HRCT and presence of lung fibrosis on HRCT. The horizontal
line indicates the mean of mRSS17total.
Additional file 4. A) Linear regression (R2) of kSSNimble with mRSS17total
of 17 body locations. The regression line assumes kSSNimble = 4 for
mRSS17total = 0. The slope m of the regression line is indicated. (B) Linear
regression of kSSR0 with mRSS17total of the 17 body locations.
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